Bide Pharmatech Co. Ltd. A
Bide Pharmatech Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. Its products are used in life sciences, organic chemistry, analytical chemistry, and other applications. The company was founded in 2007 and is based in Shanghai, China.
Bide Pharmatech Co. Ltd. A (688073) - Total Liabilities
Latest total liabilities as of June 2025: CN¥581.46 Million CNY
Based on the latest financial reports, Bide Pharmatech Co. Ltd. A (688073) has total liabilities worth CN¥581.46 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bide Pharmatech Co. Ltd. A - Total Liabilities Trend (2020–2024)
This chart illustrates how Bide Pharmatech Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bide Pharmatech Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Bide Pharmatech Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
J.Kumar Infraprojects Limited
NSE:JKIL
|
India | ₹30.75 Billion |
|
Alar Pharmaceuticals Inc.
TWO:6785
|
Taiwan | NT$69.15 Million |
|
Marr S.p.A.
LSE:0NSS
|
UK | €926.41 Million |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.22 Billion |
|
Chongqing Yukaifa Co Ltd
SHE:000514
|
China | CN¥3.18 Billion |
|
Tyro Payments Ltd
AU:TYR
|
Australia | AU$320.74 Million |
|
Yamashin-Filter Corp
PINK:YMFCF
|
USA | $4.65 Billion |
|
Shenzhen Easttop Supply Chain Management Co Ltd
SHE:002889
|
China | CN¥2.59 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Bide Pharmatech Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.31 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bide Pharmatech Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bide Pharmatech Co. Ltd. A (2020–2024)
The table below shows the annual total liabilities of Bide Pharmatech Co. Ltd. A from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥390.91 Million | +20.10% |
| 2023-12-31 | CN¥325.49 Million | +14.99% |
| 2022-12-31 | CN¥283.05 Million | +2.09% |
| 2021-12-31 | CN¥277.27 Million | +65.40% |
| 2020-12-31 | CN¥167.64 Million | -- |